Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need


H.C. Wainwright BioConnect Virtual Conference
 January 10, 2022 -
January 13, 2022

Cardiff Oncology CEO, Mark Erlander, PhD, will present at the H.C. Wainwright BioConnect virtual conference. The presentation will be available on-demand Monday, January 10th through Wednesday, January 13th, 2022. A link to the presentation is provided.